. Clinical manifestations are coarse facial features, skeletal abnormalities, mental retardation, corneal clouding, cardiac disease, and respiratory complications. A severely and rapidity progressive clinical course leads to death before 10 years of age. A deficiency of GlcNAc-phosphotransferase prevents the addition of the mannose-6-phosphate marker to lysosomal acid hydrolases. This consequently impairs the correct transport of lysosomal hydrolases to the lysosomal compartment, leading to a massive secretion of acid hydrolases in the plasma and body fluids 2) . In ML II patients, the level of lysosomal hydrolases is strikingly elevated in serum and other body fluids, and the lysosomal activities in cultured cells are decreased 3) . The prenatal diagnosis of ML II is based on the intracellular reduction in the activity of several lysosomal enzymes in cultured amniotic fluid cells and the extracellular elevation of the activity of these enzymes in the amniotic fluid 4, 5) . Tiede et al. 6) report that mutations in GNPTAB encoding the alpha/beta GlcNAc-1-phosphotransferase causes ML II. Molecular genetic testing is available for the clinical diagnosis of individuals with ML II and the prenatal diagnosis of at-risk fetuses. To date, more than 80 mutations have been reported in the GNPTAB gene [7] [8] [9] [10] [11] . When disease-causing mutations are present in a family, a prenatal diagnosis of ML II is possible through an analysis of DNA extracted from fetal cells obtained by amniocentesis or chorionic villus sampling (CVS). In this study, we report the prenatal diagnosis of three cases of ML II. We used biochemical analysis and molecular analysis in two different at-risk families. We compare the use of biochemical analysis with that of molecular analysis for the prenatal diagnosis of ML II disease.
Materials and Methods/Results

Case 1 and Case 2
In this family, the first child had died at two months of age because of respiratory failure. This infant boy was diagnosed as having ML II, based on clinical manifestations and elevated serum β-glucuronidase, β-galactosidase, β-hexosaminidase and α-mannosidase activities (Table 1) .
Prenatal diagnoses of ML II were determined during the mother's second (Case 1) and fifth (Case 2) pregnancies in 2002 and in 2007, respectively. The mother had two miscarriages after the second pregnancy in the first trimester continuously. The cause of miscarriages is unknown.
The amniotic fluid samples and cultivated amniotic cells underwent lysosomal enzyme assay for the prenatal diagnoses of ML II in both fetuses. These results are summarized in Table 1 .
In Case 1, the activity of five lysosomal enzymes -including β-glucosidase, β-glucuronidase, β-galactosidase, β-hexosaminidase and α-mannosidase -were measured and their activity was compared with normal control samples. Four lysosomal enzyme levels were reduced by 54% to 73%, compared with the control samples. Only the level of β-hexosaminidase was substantially elevated in cultivated amniotic cells. By contrast, the activity of all five enzymes in the amniotic fluid samples was a few times higher than their activity in normal controls. On the basis of these results, this fetus was not diagnosed as having ML II or as being a possible asymptomatic carrier. The pregnan cy continued and a normal child was born after a successful pregnancy. In Case 2, the activity of nine lysosomal enzymes−inclu ding α-and β-galactosidases, α-and β-glucosidases, α-and β-mannosidases, β-hexosaminidase, α-fucosidase and β-glucuronidase−was measured in cultivated amniotic cells that had been derived from at-risk fetuses and compared with a normal control. The activity of all nine enzymes was slightly reduced in the cultivated amniotic cells, but retained 36% to 95% of the activity found in the normal control. The levels of β-glucosidase, β-galactosidase, β-hexosaminidase, α-mannosidase, α-fucosidase and α-galactosidase in the amniotic fluids were measured and compared with a normal control. Four of six lysosomal enzymes were slightly increased. Based on these results, the fetus was diagnosed as not having ML II and a normal child was born.
Case 3
At 10 months old, a first-born girl was diagnosed as having ML II, based on the abnormal intracellular-extracellular distribution of the activity of lysosomal enzymes. The activity of plasma α-and β-galactosidases, β-hexosaminidase and α-mannosidase was grossly elevated, whereas the activity of the lysosomal enzymes was marginally diminished in her leucocytes (data not shown). A mutation analysis of the GNPTAB gene (performed when she was one year and four months old) showed that she was a compound heterozygote of nonsense mutations (Q104X; c.310 C>T and R1189X; c.3565 C>T). These mutations have been already reported in the medical literature 7, 8) . Molecular genetic testing on the child's parents revealed that the Q104X mutation presented in the maternal allele and the R1189X mutation presented in the paternal allele. Her parents were not consanguineous. She died at the age of 4 years 8 months due to a respiratory infection.
For the second pregnancy, the parents requested a prenatal diagnosis. Therefore, CVS was performed at 11 weeks and 1 day of gestation. The disease-causing mutations were not detected in either of the alleles. The fetus was diagnosed as not having ML II, and a healthy baby was born after a successful pregnancy.
Discussion
We diagnosed three cases of prenatal ML II in two families whose first child had ML II. In Case 1, the prenatal diagnosis resulted from a lysosomal enzyme assay of the mother's amniotic fluid samples and cultivated amniotic cells. Genetic testing for ML II was unavailable at that time since GNPTAB gene sequencing has only been available since 2005. Therefore, the prenatal diagnosis depended on a biochemical analysis of the activity of lysosomal enzymes in the amniotic fluid samples and cultivated amniotic cells. Based on the slight elevation in the activity of the enzymes in the mother's amniotic fluid samples, the fetus was a presumed carrier. In Case 2, a prenatal diagnosis again relied on biochemical analysis since we had not identified the diseasecausing mutations in the proband of this family. In Case 3, a mutation analysis of the GNPTAB gene had already been performed and the disease-causing mutations in the family had been determined. The DNA analysis showed the fetus had normal alleles. This indicated that this fetus was clearly not affected (Table 2) .
In this study, we compared two procedures -biochemical analysis and molecular analysis -for the prenatal diagnosis of ML II. The comparison of these two methods is summarized in Table 3 .
Both methods require an invasive procedure to obtain specimens for the diagnosis. In addition, there is a 1% to 2% risk of fetal and prenatal loss. Since the 1970s, a prenatal diagnosis of ML II has relied on measuring the activity of lysosomal enzymes in amniotic fluid samples and cultivated amniotic cells 12) . In our experience, a biochemical analysis requires obtaining cell cultures from amniotic fluid for more than two weeks to provide a sufficient amount of cells for a confidence result. This means that a prenatal diagnosis, involving the use of amniotic fluid samples and cultivated amniotic cells obtained through amniocentesis at 16 to 18 weeks of gestation, would result in a late diagnosis at 19 to 22 weeks of gestation. In addition, the method should be performed in a confined laboratory and require amniotic samples from normal pregnant controls who have been subjected to the same conditions. Nevertheless, this method is still useful.
Biochemical tests have one significant advantage over DNA analysis. Biochemical analysis can directly detect disease-causing abnormalities. Moreover, the measurement of the UDP-N-acetylglucosamine: N-acetylglucosaminyl-1-phosphotransferase activity has an advantage over measurements based on detecting an abnormal intracellular-extracellular distribution of the activity of lysosomal enzymes.
Molecular genetic testing by direct sequence analysis is usually possible when mutations are confirmed in the proband. Mutation analysis that can reveal the affected (homozygote), unaffected (normal), and the heterozygote is distinctly preferred for disorders in which enzyme analysis is complicated and miss-prone. For example, the measured activity level of lysosomal enzymes is between that expected for a heterozygote and the patient's range. Molecular analysis has an advantage in that it can be performed during the first-trimester (as early as 11 to 13 weeks of gestation), whereas amniocentesis is usually performed during the midtrimester. Therefore, molecular diagnosis is a preferable method when a prompt decision is necessary.
